GPP
SCMP

Great Point Partners’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Great Point Partners’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-450,000
Closed -$7M – 45
2015
Q1 		$7M Buy
+450,000
New +$6.98M 3.08% 12

Other funds holding SCMP

GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Great Point Partners's SCMP Position: Q2 2015 in Review

Great Point Partners sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2015, closing a stake of 450,000 shares — an estimated $7M sold.

Great Point Partners first reported a position in SCMP in Q1 2015 and held it in 1 quarter. The position peaked at $7M in Q1 2015. 130 funds tracked by Wall St. Rank hold SCMP as of Q2 2015.

  • Great Point Partners reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Great Point Partners sold 450,000 Sucampo Pharmaceuticals, Inc. shares in Q2 2015, an estimated $7M.
  • Great Point Partners first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • Great Point Partners's Sucampo Pharmaceuticals, Inc. position peaked at $7M in Q1 2015.
  • 130 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2015.

Based on Great Point Partners's 13F filing for Q2 2015, filed 14 Aug 2015.